Peña R B, Cadavid A P, Botero J H, García G P, Gallego M I, Ossa J E
Reproduction Program, School of Medicine, University of Antioquia, Medellín-Colombia.
Am J Reprod Immunol. 1998 Feb;39(2):120-4. doi: 10.1111/j.1600-0897.1998.tb00343.x.
The questions of whether production of mixed lymphocyte reaction-blocking factors (MLR-BFs) after immunotherapy with lymphocytes for recurrent spontaneous abortion (RSA) has prognostic value and whether cytotoxic antibodies are also involved were tested.
A prospective study with 33 patients who had a history of two or more abortions, lacking MLR-BFs, was carried out. The patients received immunizations with lymphocytes and 6 weeks or later were tested for seroconversion of MLR-BFs. Seventeen of these thirty-three patients were evaluated for antipaternal cytotoxic antibodies. The results were correlated with the outcome of the next pregnancy after treatment.
Eighty percent of the 33 patients had a live child. Of those patients having success, only 50% produced MLR-BFs. Of those patients having a new loss, five did and two did not produce MLR-BF (P > 0.05). Regarding the 17 patients tested for cytotoxic antibodies, 4 of the 5 patients who tested positive had a new abortion, whereas only 1 of 12 whose tests remained negative did not have gestational success (P < 0.01).
The presence of MLR-BFs is not a prognostic criterium for the outcome of pregnancy after alloimmunotherapy, and, consequently, it is not a good diagnostic tool for RSA of alloimmune cause.
对复发性自然流产（RSA）患者进行淋巴细胞免疫治疗后产生的混合淋巴细胞反应阻断因子（MLR - BF）是否具有预后价值以及细胞毒性抗体是否也参与其中进行了研究。
对33例有两次或更多次流产史且缺乏MLR - BF的患者进行了一项前瞻性研究。患者接受淋巴细胞免疫治疗，6周或更晚时检测MLR - BF的血清转化情况。对这33例患者中的17例进行了抗父本细胞毒性抗体评估。结果与治疗后下一胎妊娠结局相关。
33例患者中有80%产下活婴。在妊娠成功的患者中，只有50%产生了MLR - BF。在再次流产的患者中，5例产生了MLR - BF，2例未产生（P>0.05）。在检测细胞毒性抗体的17例患者中，5例检测呈阳性的患者中有4例再次流产，而12例检测仍为阴性的患者中只有1例妊娠未成功（P<0.01）。
MLR - BF的存在不是同种异体免疫治疗后妊娠结局的预后标准，因此，它不是同种免疫原因导致的RSA的良好诊断工具。
